MYLERAN Side Effects

6872200-2 | Abdominal Pain, Diarrhoea, Dizziness, Overdose
on Oct 19, 2009 Male patient from UNITED STATES , 58 years of age, was diagnosed with amyloidosis and was treated with Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), diarrhoea, dizziness (What is dizziness?), overdose. Myleran dosage: 32mg Per Day. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

6004070-9 | Hearing Impaired
Patient was taking Myleran (View Usage). Patient had the following side effects: hearing impaired on Dec 10, 2008 from SWEDEN Additional patient health information: Male patient , 27 years of age, was diagnosed with lymphoma (What is lymphoma?) and. Myleran dosage: . During the same period patient was treated with FLUDARA (60mg Per Day) (View Fludara Review and Fludara Label ), FRESENIUS (View Fresenius Review and Fresenius Label ), URSO FALK (View Urso Falk Review and Urso Falk Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), SANDIMMUNE (View Sandimmune Review and Sandimmune Label ), FRAGMIN (View Fragmin Review and Fragmin Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (View Sulfamethoxazole And Trimethoprim Double Strength Review and Sulfamethoxazole And Trimethoprim Double Strength Label ), EMGESAN (View Emgesan Review and Emgesan Label ).

5903323-X | Ageusia, Aphthous Stomatitis, Paraesthesia, Polyneuropathy
Adverse event was reported on Sep 25, 2008 by a Female patient taking Myleran (View Usage) (Dosage: 4mg Per Day) . Location: GERMANY , 55 years of age, weighting 110.2 lb, After Myleran was administered, patient had the following side effects: ageusia, aphthous stomatitis, paraesthesia, polyneuropathy.

5609697-1 | Brain Oedema, Cardiovascular Insufficiency, Hepatomegaly, Pulmonary Oedema, Respiratory Failure, Venoocclusive Disease
on Jan 22, 2008 Female patient from POLAND , child 5 years of age, weighting 44.09 lb, was treated with Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: brain oedema, cardiovascular insufficiency, hepatomegaly, pulmonary oedema, respiratory failure, venoocclusive disease. Myleran dosage: . During the same period patient was treated with VP 16 (View Vp-16 Review and Vp-16 Label ), ENDOXAN (View Endoxan Review and Endoxan Label ).


5512944-8 | Pulmonary Fibrosis
on Nov 08, 2007 Female patient from UNITED STATES , 86 years of age, was diagnosed with polycythaemia vera and was treated with Myleran (View Usage). Patient had the following side effects: pulmonary fibrosis (What is pulmonary fibrosis?). Myleran dosage: . During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), THYROID TAB (View Thyroid Tab Review and Thyroid Tab Label ), HYDROXYUREA (View Hydroxyurea Review and Hydroxyurea Label ).

5363593-6 | Atelectasis, Dyspnoea, Lung Cyst Benign, Lung Infiltration, Obstructive Airways Disorder, Pulmonary Fibrosis
Patient was taking Myleran (View Usage). After Myleran was administered, patient had the following side effects: atelectasis, dyspnoea, lung cyst benign, lung infiltration, obstructive airways disorder, pulmonary fibrosis (What is pulmonary fibrosis?) on Jun 12, 2007 from FRANCE Additional patient health information: Female patient , 47 years of age, weighting 121.3 lb, . Myleran dosage: 8mg Per Day. During the same period patient was treated with ALKERAN (230mg Per Day) (View Alkeran Review and Alkeran Label ), MELPHALAN (View Melphalan Review and Melphalan Label ). Patient was hospitalized.

5127290-4 | Abdominal Pain, Activated Partial Thromboplastin Time Prolonged, Ascites, Cerebral Haemorrhage, Complications Of Bone Marrow Transplant, Diarrhoea, Flatulence, Haemodialysis, Hepatic Failure
Adverse event was reported on Sep 29, 2006 by a Female patient taking Myleran (View Usage) (Dosage: ) was diagnosed with bone marrow conditioning regimen and. Location: GERMANY , 55 years of age, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), activated partial thromboplastin time prolonged, ascites, cerebral haemorrhage, complications of bone marrow transplant, diarrhoea, flatulence, haemodialysis, hepatic failure. During the same period patient was treated with ANTITHYMOCYTE IG (View Antithymocyte Ig Review and Antithymocyte Ig Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), CYCLOPHOSPHAMIDE (60 Mg/kg/intravenous) (View Cyclophosphamide Review and Cyclophosphamide Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ).

5106555-6 | Atelectasis, Dyspnoea, Lung Cyst Benign, Lung Infiltration, Obstructive Airways Disorder, Pulmonary Fibrosis
on Aug 24, 2006 Female patient from FRANCE , 47 years of age, weighting 121.3 lb, was diagnosed with acute leukaemia and was treated with Myleran (View Usage). Patient had the following side effects: atelectasis, dyspnoea, lung cyst benign, lung infiltration, obstructive airways disorder, pulmonary fibrosis (What is pulmonary fibrosis?). Myleran dosage: 8mg Per Day. During the same period patient was treated with ALKERAN (230mg Per Day) (View Alkeran Review and Alkeran Label ), MELPHALAN (View Melphalan Review and Melphalan Label ). Patient was hospitalized.

5095334-4 | Atelectasis, Dyspnoea, Lung Cyst Benign, Lung Infiltration, Pulmonary Fibrosis
on Aug 24, 2006 Female patient from FRANCE , 47 years of age, weighting 121.3 lb, was diagnosed with acute leukaemia and was treated with Myleran (View Usage). After Myleran was administered, patient had the following side effects: atelectasis, dyspnoea, lung cyst benign, lung infiltration, pulmonary fibrosis (What is pulmonary fibrosis?). Myleran dosage: 4unit Per Day. During the same period patient was treated with MELPHALAN (View Melphalan Review and Melphalan Label ). Patient was hospitalized.

5087223-6 | Cerebral Atrophy, Oedema
Patient was taking Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral atrophy, oedema on Aug 03, 2006 from CANADA Additional patient health information: Male patient , 54 years of age, . Myleran dosage: 12.8 Mg/kg Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (120 Mg/kg Intravenous) (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (45 Mg/m2 Intravenous) (View Methotrexate Review and Methotrexate Label ), CYCLOSPORINE (1.5 Mg/kg See Dosage Text) (View Cyclosporine Review and Cyclosporine Label ).

5063371-1 | Laboratory Test Abnormal
Adverse event was reported on Dec 27, 2005 by a Male patient taking Myleran (View Usage) (Dosage: 3tab Per Day) . Location: UNITED STATES , 73 years of age, Patient had the following side effects: laboratory test abnormal.

4805358-7 | Haemodialysis, International Normalised Ratio Increased, Renal Impairment, Respiratory Failure, Sepsis, Venoocclusive Liver Disease
on Oct 05, 2005 Female patient from UNITED KINGDOM , 36 years of age, was treated with Myleran (View Usage). After Myleran was administered, patient had the following side effects: haemodialysis, international normalised ratio increased, renal impairment, respiratory failure, sepsis (What is sepsis?), venoocclusive liver disease. Myleran dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

4805356-3 | Encephalopathy, Hepatic Rupture, Peritoneal Haemorrhage, Venoocclusive Liver Disease
on Oct 05, 2005 Female patient from UNITED KINGDOM , 34 years of age, was treated with Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: encephalopathy, hepatic rupture, peritoneal haemorrhage, venoocclusive liver disease. Myleran dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), THIACETAZONE (View Thiacetazone Review and Thiacetazone Label ).

4805329-0 | Ascites, Encephalopathy, International Normalised Ratio Increased, Multi-organ Failure, Venoocclusive Liver Disease
Patient was taking Myleran (View Usage). Patient had the following side effects: ascites, encephalopathy, international normalised ratio increased, multi-organ failure, venoocclusive liver disease on Oct 05, 2005 from UNITED KINGDOM Additional patient health information: Male patient , 49 years of age, . Myleran dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

4749071-3 | Pneumonitis, Pulmonary Toxicity, Pyrexia, Respiratory Failure
Adverse event was reported on Aug 10, 2005 by a Male patient taking Myleran (View Usage) (Dosage: 1 Mg/kg/four Times Per Day/oral) was diagnosed with mantle cell lymphoma and. Location: AUSTRALIA , 58 years of age, After Myleran was administered, patient had the following side effects: pneumonitis, pulmonary toxicity, pyrexia, respiratory failure. During the same period patient was treated with ALKERAN (140 Mg/m2/ Intravenous) (View Alkeran Review and Alkeran Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), CO TRIMOXAZOLE (View Co-trimoxazole Review and Co-trimoxazole Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ).

4749070-1 | Blood Immunoglobulin G Decreased, Cough, Influenza, Lung Infiltration, Pneumonitis, Pulmonary Toxicity, Respiratory Failure, Sepsis, Streptococcal Infection
on Aug 10, 2005 Male patient from AUSTRALIA , 61 years of age, was diagnosed with mantle cell lymphoma and was treated with Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: blood immunoglobulin g decreased, cough, influenza, lung infiltration, pneumonitis, pulmonary toxicity, respiratory failure, sepsis (What is sepsis?), streptococcal infection (What is streptococcal infection?). Myleran dosage: 1 Mg/kg/four Times Per Day/oral. During the same period patient was treated with MELPHALAN (View Melphalan Review and Melphalan Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), CO TRIMOXAZOLE (View Co-trimoxazole Review and Co-trimoxazole Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ).

4749068-3 | Acute Respiratory Distress Syndrome, Pneumonitis, Pulmonary Toxicity, Respiratory Failure
on Aug 10, 2005 Female patient from AUSTRALIA , 64 years of age, was diagnosed with mantle cell lymphoma and was treated with Myleran (View Usage). Patient had the following side effects: acute respiratory distress syndrome, pneumonitis, pulmonary toxicity, respiratory failure. Myleran dosage: 1 Mg/kg/four Times Per Day/oral. During the same period patient was treated with ALKERAN (140 Mg/m2,intravenous) (View Alkeran Review and Alkeran Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), CO TRIMOXAZOLE (View Co-trimoxazole Review and Co-trimoxazole Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), CORTICOSTEROID (View Corticosteroid Review and Corticosteroid Label ).

4709621-X | Bacteria Blood Identified, Bone Marrow Depression, Bone Marrow Disorder, Escherichia Infection, Febrile Neutropenia, Fibrosis, Gastroenteritis, Lung Infiltration
Patient was taking Myleran (View Usage). After Myleran was administered, patient had the following side effects: bacteria blood identified, bone marrow depression, bone marrow disorder, escherichia infection, febrile neutropenia, fibrosis, gastroenteritis (What is gastroenteritis?), lung infiltration on Jun 20, 2005 from INDIA Additional patient health information: Female patient , 46 years of age, was diagnosed with chronic myeloid leukaemia and. Myleran dosage: . During the same period patient was treated with INTERFERON ALFA (INTERFERON ALFA) (Subcutaneous) (View Interferon Alfa (interferon Alfa) Review and Interferon Alfa (interferon Alfa) Label ), IMATINIB MESYLATE (IMATINIB MESY (View Imatinib Mesylate (imatinib Mesy Review and Imatinib Mesylate (imatinib Mesy Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

4633883-0 | Aspergillosis, Graft Dysfunction, Graft Versus Host Disease
Adverse event was reported on Apr 01, 2005 by a Male patient taking Myleran (View Usage) (Dosage: 4 Mg/kg/variable Dose/ Unk) . Location: , 67 years of age, Patient experienced the following unwanted or unexpected effects: aspergillosis, graft dysfunction, graft versus host disease. During the same period patient was treated with FLUDARABINE PHOSPHATE (Intravenous) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTIHYMOCYTE IG (View Antihymocyte Ig Review and Antihymocyte Ig Label ), GRANULOCYTE COL. STIM. FACT (View Granulocyte Col. Stim. Fact Review and Granulocyte Col. Stim. Fact Label ).

4633878-7 | Graft Versus Host Disease
on Apr 01, 2005 Male patient from , 38 years of age, was treated with Myleran (View Usage). Patient had the following side effects: graft versus host disease. Myleran dosage: 4 Mg/kg/ Variable Dose. During the same period patient was treated with FLUDARABINE PHOSPHATE (Intravenous) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTITHYMOCYTE IG (View Antithymocyte Ig Review and Antithymocyte Ig Label ), GRANULOCYTE COL. STIM. FACT (View Granulocyte Col. Stim. Fact Review and Granulocyte Col. Stim. Fact Label ).

4633874-X | Ascites, Hepatic Failure
on Apr 01, 2005 Male patient from , 55 years of age, was treated with Myleran (View Usage). After Myleran was administered, patient had the following side effects: ascites, hepatic failure. Myleran dosage: 4 Mg/kg/ Variable Dose. During the same period patient was treated with FLUDARABINE PHOSPHATE (Intravenous) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ANTITHYMOCYTE IG (View Antithymocyte Ig Review and Antithymocyte Ig Label ), GRANULOCYTE COL. STIM. FACT (View Granulocyte Col. Stim. Fact Review and Granulocyte Col. Stim. Fact Label ).

4630696-0 | Febrile Neutropenia, Gastrointestinal Toxicity, Sepsis
Patient was taking Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, gastrointestinal toxicity, sepsis (What is sepsis?) on Mar 22, 2005 from Additional patient health information: Male patient , 14 years of age, . Myleran dosage: See Dosage Text, Oral. During the same period patient was treated with THIOTEPA (Intravenous) (View Thiotepa Review and Thiotepa Label ), GRANULOCYTE (View Granulocyte Review and Granulocyte Label ).

4630690-X | Febrile Neutropenia, Gastrointestinal Toxicity, Venoocclusive Disease
Adverse event was reported on Mar 22, 2005 by a Male patient taking Myleran (View Usage) (Dosage: See Dosage Text, Oral) . Location: , child 12 years of age, Patient had the following side effects: febrile neutropenia, gastrointestinal toxicity, venoocclusive disease. During the same period patient was treated with THIOTEPA (Intravenous) (View Thiotepa Review and Thiotepa Label ), GRANULOCYTE (View Granulocyte Review and Granulocyte Label ).

4630689-3 | Bone Sarcoma, Febrile Neutropenia, Gastrointestinal Toxicity
on Mar 22, 2005 Male patient from , child 5 years of age, was treated with Myleran (View Usage). After Myleran was administered, patient had the following side effects: bone sarcoma, febrile neutropenia, gastrointestinal toxicity. Myleran dosage: See Dosage Text, Oral. During the same period patient was treated with THIOTEPA (Intravenous) (View Thiotepa Review and Thiotepa Label ), GRANULOCYTE (View Granulocyte Review and Granulocyte Label ).

4630688-1 | Febrile Neutropenia, Gastrointestinal Toxicity, Sepsis
on Mar 22, 2005 Female patient from , 15 years of age, was treated with Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, gastrointestinal toxicity, sepsis (What is sepsis?). Myleran dosage: See Dosage Text, Oral. During the same period patient was treated with ALKERAN (Intravenous Infusion) (View Alkeran Review and Alkeran Label ), GRANULOCYTE (View Granulocyte Review and Granulocyte Label ).

4630685-6 | Febrile Neutropenia, Gastrointestinal Toxicity, Sepsis
Patient was taking Myleran (View Usage). Patient had the following side effects: febrile neutropenia, gastrointestinal toxicity, sepsis (What is sepsis?) on Mar 22, 2005 from Additional patient health information: Female patient , child 6 years of age, . Myleran dosage: See Dosage Text, Oral. During the same period patient was treated with ALKERAN (Intravenous Infusion) (View Alkeran Review and Alkeran Label ), GRANULOCYTE (View Granulocyte Review and Granulocyte Label ).

4629548-1 | Febrile Neutropenia, Gastrointestinal Toxicity
Adverse event was reported on Mar 22, 2005 by a Male patient taking Myleran (View Usage) (Dosage: Oral) . Location: , child 4 years of age, After Myleran was administered, patient had the following side effects: febrile neutropenia, gastrointestinal toxicity. During the same period patient was treated with ALKERAN (Intravenous Infusion) (View Alkeran Review and Alkeran Label ), HYCAMTIN (Intravenous Infusion) (View Hycamtin Review and Hycamtin Label ), GRANULOCYTE COL. STIM.FACT. (View Granulocyte Col. Stim.fact. Review and Granulocyte Col. Stim.fact. Label ).

4629545-6 | Engraftment Syndrome, Febrile Neutropenia, Gastrointestinal Toxicity
on Mar 22, 2005 Female patient from , child 9 years of age, was treated with Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: engraftment syndrome, febrile neutropenia, gastrointestinal toxicity. Myleran dosage: Oral. During the same period patient was treated with ALKERAN (View Alkeran Review and Alkeran Label ), HYCAMTIN (Intravenous Infusion) (View Hycamtin Review and Hycamtin Label ), GRANULOCYTE COL. STIM. FACT (View Granulocyte Col. Stim. Fact Review and Granulocyte Col. Stim. Fact Label ).

4629544-4 | Engraftment Syndrome, Febrile Neutropenia, Gastrointestinal Toxicity, Sepsis
on Mar 22, 2005 Female patient from , child 5 years of age, was treated with Myleran (View Usage). Patient had the following side effects: engraftment syndrome, febrile neutropenia, gastrointestinal toxicity, sepsis (What is sepsis?). Myleran dosage: Oral. During the same period patient was treated with ALKERAN (Intravenous Infusion) (View Alkeran Review and Alkeran Label ), THIOTEPA (Intravenous) (View Thiotepa Review and Thiotepa Label ), GRANULOCYTE COL. STIM.FACT. (View Granulocyte Col. Stim.fact. Review and Granulocyte Col. Stim.fact. Label ).

4629340-8 | Engraftment Syndrome, Febrile Neutropenia, Gastrointestinal Toxicity, Venoocclusive Disease
Patient was taking Myleran (View Usage). After Myleran was administered, patient had the following side effects: engraftment syndrome, febrile neutropenia, gastrointestinal toxicity, venoocclusive disease on Mar 22, 2005 from Additional patient health information: Male patient , child 4 years of age, . Myleran dosage: See Dosage Text Oral. During the same period patient was treated with THIOTEPA (Intravenous) (View Thiotepa Review and Thiotepa Label ), GRANULOCYTE COL. STIM. FACT (View Granulocyte Col. Stim. Fact Review and Granulocyte Col. Stim. Fact Label ).

4629337-8 | Engraftment Syndrome, Febrile Neutropenia, Gastrointestinal Toxicity
Adverse event was reported on Mar 22, 2005 by a Female patient taking Myleran (View Usage) (Dosage: See Dosage Text Oral) . Location: , 14 years of age, Patient experienced the following unwanted or unexpected effects: engraftment syndrome, febrile neutropenia, gastrointestinal toxicity. During the same period patient was treated with ALKERAN (Intravenous Infusion) (View Alkeran Review and Alkeran Label ), GRANULOCYTE COL. STIM. FACT (View Granulocyte Col. Stim. Fact Review and Granulocyte Col. Stim. Fact Label ).

4626839-5 | Complications Of Bone Marrow Transplant, Febrile Neutropenia, Gastrointestinal Toxicity, Sepsis
on Mar 22, 2005 Male patient from , child 3 years of age, was treated with Myleran (View Usage). Patient had the following side effects: complications of bone marrow transplant, febrile neutropenia, gastrointestinal toxicity, sepsis (What is sepsis?). Myleran dosage: Oral. During the same period patient was treated with ALKERAN (Intravenous Infusion) (View Alkeran Review and Alkeran Label ), GRANULOCYTE COL.STIM. FACT (View Granulocyte Col.stim. Fact Review and Granulocyte Col.stim. Fact Label ).

4626838-3 | Febrile Neutropenia, Gastrointestinal Toxicity, Transplant Failure
on Mar 22, 2005 Male patient from , child 5 years of age, was treated with Myleran (View Usage). After Myleran was administered, patient had the following side effects: febrile neutropenia, gastrointestinal toxicity, transplant failure. Myleran dosage: Oral. During the same period patient was treated with ALKERAN (Intravenous Infusion) (View Alkeran Review and Alkeran Label ), GRANULOCYTE COL.STIM.FACT (View Granulocyte Col.stim.fact Review and Granulocyte Col.stim.fact Label ).

4626837-1 | Engraftment Syndrome, Febrile Neutropenia, Gastrointestinal Toxicity
Patient was taking Myleran (View Usage). Patient experienced the following unwanted or unexpected effects: engraftment syndrome, febrile neutropenia, gastrointestinal toxicity on Mar 22, 2005 from Additional patient health information: Male patient , 15 years of age, . Myleran dosage: See Dosage Text / Oral. During the same period patient was treated with ALKERAN (Intravenous Infusion) (View Alkeran Review and Alkeran Label ), HYCAMTIN (Intravenous Infusion) (View Hycamtin Review and Hycamtin Label ), GRANULOCYTE COL.STIM.FACT (View Granulocyte Col.stim.fact Review and Granulocyte Col.stim.fact Label ).

4621370-5 | Anaemia Haemolytic Autoimmune
Adverse event was reported on Mar 14, 2005 by a Male patient taking Myleran (View Usage) (Dosage: ) . Location: , 40 years of age, Patient had the following side effects: anaemia haemolytic autoimmune. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ).

4607695-8 | Accidental Overdose, Convulsion, Cytomegalovirus Infection, Graft Versus Host Disease, Hyperbilirubinaemia, Multi-organ Failure, Sepsis
on Feb 21, 2005 Female patient from , 14 years of age, was treated with Myleran (View Usage). After Myleran was administered, patient had the following side effects: accidental overdose, convulsion, cytomegalovirus infection (What is cytomegalovirus infection?), graft versus host disease, hyperbilirubinaemia, multi-organ failure, sepsis (What is sepsis?). Myleran dosage: See Dosage Text. During the same period patient was treated with ANTITHYMOCYTE IG (View Antithymocyte Ig Review and Antithymocyte Ig Label ).